Detalles de la búsqueda
1.
Persistence of Anti-SE36 Antibodies Induced by the Malaria Vaccine Candidate BK-SE36/CpG in 5-10-Year-Old Burkinabe Children Naturally Exposed to Malaria.
Vaccines (Basel)
; 12(2)2024 Feb 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38400149
2.
Plasmodium falciparum infection coinciding with the malaria vaccine candidate BK-SE36 administration interferes with the immune responses in Burkinabe children.
Front Immunol
; 14: 1119820, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36993981
3.
Safety and immunogenicity of BK-SE36/CpG malaria vaccine in healthy Burkinabe adults and children: a phase 1b randomised, controlled, double-blinded, age de-escalation trial.
Front Immunol
; 14: 1267372, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37908361
4.
African-specific polymorphisms in Plasmodium falciparum serine repeat antigen 5 in Uganda and Burkina Faso clinical samples do not interfere with antibody response to BK-SE36 vaccination.
Front Cell Infect Microbiol
; 12: 1058081, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36590593
5.
Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.
Front Immunol
; 13: 978591, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36119062
Resultados
1 -
5
de 5
1
Próxima >
>>